Health Affairs September 19, 2024
Although public attention to U.S. vaccination policy has receded from its COVID-19-era peak, the past several months have been extraordinarily busy for public health agencies and their expert advisors. So far this year, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have updated the composition and recommended use of influenza and COVID-19 vaccines for the approaching 2024-25 season, considered the use of vaccines in response to mpox and H5N1 influenza outbreaks, and provided increasingly nuanced, population-specific guidance for routine vaccines (such as those against respiratory syncytial virus (RSV)), among other activities. The U.S. vaccine policy landscape is broader and changing more rapidly than at any point in its modern history, and those guiding it...
Today's Sponsors
Today's Sponsor